<DOC>
	<DOCNO>NCT01453504</DOCNO>
	<brief_summary>The purpose trial 1. determine recommend dose everolimus subsequent Phase II trial 2. determine efficacy everolimus plus DHAP</brief_summary>
	<brief_title>Everolimus Combination With DHAP Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>relapsed refractory Hodgkin Lymphoma age 1860 histology confirm relapse previous therapy mTOR inhibitor current CNS involvement primary malignant disease within last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>